ClearPoint Neuro, Inc.
CLPTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in. At a $425.8M market cap, ClearPoint Neuro, Inc. ranks as a small-cap company within healthcare. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
Market Cap
$425.8M
Beta
1.27
P/E (TTM)
—
P/E (Fwd)
-11.68
EPS (TTM)
$-1.18
EPS (Fwd)
$-1.20
ROE
-226.5%
ROA
-24.4%
Cash
$29.4M
Total Debt
$63.9M
Free CF
-$14.1M
52W Change
27.5%
Annual Financials
Cash vs Debt
Where CLPT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CLPT finished 8.49% above its 150-day moving average ($13.19) and 6.55% above its 200-day moving average ($13.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLPT overbought or oversold?
At the September 3, 2026 close, CLPT's RSI(14) was 42.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CLPT has $29.4M in cash with $63.9M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$14.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -226.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $20.6M (2022) to $37.0M (2025), reflecting a 80% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CLPT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.